Literature DB >> 16648863

Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis.

Jorge S Reis-Filho1, Kay Savage, Maryou B K Lambros, Michelle James, Dawn Steele, Robin L Jones, Mitch Dowsett.   

Abstract

Conflicting results on the prevalence of cyclin D1 ovexpression and its correlation with CCND1 amplification and outcome of breast cancer patients have been reported. Owing to limited sensitivity and specificity of most antibodies against cyclin D1, evaluation of cyclin D1 immunoexpression is reported to be problematic. The aims of this study were to assess the prevalence of cyclin D1 expression in breast carcinomas using the SP4 rabbit monoclonal antibody; to correlate cyclin D1 expression with amplification, assessed using chromogenic in situ hybridisation (CISH); and to analyse the relationship between CCND1 amplification and overexpression with clinicopathological parameters and outcome in a tissue microarray containing replicate tumour samples from 245 breast cancer patients. Immunohistochemistry for cyclin D1 was performed using the SP4 and the results were scored according to the Allred scoring system. CISH was carried out using the Zymed CCND1 SpotLight probe. CISH signals were counted in 60 morphologically unequivocal neoplastic cells. Amplification was defined as >5 signals per nucleus in more than 50% of cancer cells, or when large gene copy clusters were seen. Strong cyclin D1 expression and CCND1 amplification were found in 67.4 and 14.5% of the cases, respectively. A strong correlation between cyclin D1 overexpression and CCND1 amplification was demonstrated (P<0.0001). Cyclin D1 expression showed a positive correlation with hormone receptor expression (both ER and PgR, P<0.0001). An inverse correlation was observed between an immunohistochemical panel of 'basal-like' markers and both cyclin D1 overexpression (P<0.0001) and CCND1 amplification (P<0.0001). On univariate analysis cyclin D1 expression showed a correlation with longer overall survival (OS). Neither cyclin D1 nor CCND1 were independent prognostic factors for disease-free survival or OS. The results of this study confirm the association between cyclin D1 overexpression and positivity for hormone receptors and the lack of CCND1 amplification in basal-like breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648863     DOI: 10.1038/modpathol.3800621

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  51 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

2.  Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma.

Authors:  Tamanna Parvin; Chhanda Das; Manoj Choudhury; Bitan Kumar Chattopadhyay; Madhumita Mukhopadhyay
Journal:  Indian J Surg Oncol       Date:  2018-11-30

3.  Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Authors:  Hege G Russnes; Hans Kristian Moen Vollan; Ole Christian Lingjærde; Alexander Krasnitz; Pär Lundin; Bjørn Naume; Therese Sørlie; Elin Borgen; Inga H Rye; Anita Langerød; Suet-Feung Chin; Andrew E Teschendorff; Philip J Stephens; Susanne Månér; Ellen Schlichting; Lars O Baumbusch; Rolf Kåresen; Michael P Stratton; Michael Wigler; Carlos Caldas; Anders Zetterberg; James Hicks; Anne-Lise Børresen-Dale
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

4.  Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands.

Authors:  Orsolya Kiss; Anna-Mária Tőkés; Semir Vranic; Zoran Gatalica; László Vass; Nóra Udvarhelyi; A Marcell Szász; Janina Kulka
Journal:  Virchows Arch       Date:  2015-08-21       Impact factor: 4.064

5.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

6.  QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer.

Authors:  Sheng Zhang; Yingbo Shao; Guofang Hou; Jingchao Bai; Weiping Yuan; Linping Hu; Tao Cheng; Anders Zetterberg; Jin Zhang
Journal:  Tumour Biol       Date:  2013-10-05

7.  Expression of Cyclin D1 Is Associated with β-Catenin Expression and Correlates with Good Prognosis in Colorectal Adenocarcinoma.

Authors:  Kyu Yun Jang; Yo Na Kim; Jun Sang Bae; Myoung Ja Chung; Woo Sung Moon; Myoung Jae Kang; Dong Geun Lee; Ho Sung Park
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 8.  Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Authors:  Aaron M Gruver; Ziad Peerwani; Raymond R Tubbs
Journal:  J Clin Pathol       Date:  2010-03       Impact factor: 3.411

Review 9.  Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models.

Authors:  Gwen E Dressing; Christy R Hagan; Todd P Knutson; Andrea R Daniel; Carol A Lange
Journal:  Endocr Relat Cancer       Date:  2009-04-08       Impact factor: 5.678

10.  Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.

Authors:  Zhishuang Li; Jingjing Cui; Qiong Yu; Xiaojuan Wu; Aifeng Pan; Li Li
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.